Navigation Links
Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
Date:3/7/2012

ANN ARBOR, Mich., March 7, 2012 /PRNewswire/ -- Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer, will present at the ROTH Capital Partners 24th Annual Growth Stock Conference. The conference will be held March 11-14, 2012 at The Ritz Carlton in Dana Point, CA. Mr. Riley will present on Wednesday, March 14, 2012 at 2:30pm (PT).

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at http://wsw.com/webcast/roth26/syn/. After the presentation, a replay will be archived and accessible for 14 days at the same website.

ROTH Capital Partners, LLC

ROTH Capital Partners, LLC (ROTH) is a relationship-driven investment bank focused on identifying growth opportunities for corporate and institutional clients. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading and market-making services. Headquartered in Newport Beach, CA, ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S., Hong Kong and a Shanghai Representative Office. For more information on ROTH, please visit www.roth.com.

About Synthetic Biologics, Inc.

Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
2. The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems
3. RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
4. Synthetic Biology Importance in the 21st Century
5. Synthetic Biology: The Next Biotech Revolution Is Brewing
6. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
7. Synthetic Biology on the Rise
8. Does Synthetic Biology Need Synthesized Ethics?
9. Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae
10. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
11. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2020)... Texas (PRWEB) , ... January 28, 2020 , ... ... to be the exclusive distributor to food and beverage manufactures within North ... are considered critical suppliers. This agreement will allow each company to pool their ...
(Date:1/27/2020)... , ... January 27, 2020 , ... ... it has secured financing from strategic investors led by Halma plc , ... existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant CEO ... industry at two recent North American investor forums specializing in medical advancements. New ... Technologies & Diagnostics Forum on November 21, 2019 in New York City, and ...
(Date:1/22/2020)... Conn. (PRWEB) , ... January 21, 2020 , ... ... (CTC) liquid biopsy from a simple blood draw, today announced the sale of the ... Health. The Rare Scope will be used in clinical cancer research. , “The RareScope ...
Breaking Biology Technology:
(Date:2/13/2020)... ... February 13, 2020 , ... Pharmica Consulting ... clinical operations executives and focusing on all facets of clinical trial planning and ... patient engagement, and more. , “We have attended the SCOPE Summit every ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... for life sciences companies and government agencies, announced the recent appointment of ... expertise to Tunnell, with significant experience assessing, designing, and managing enterprise transformation ...
(Date:2/7/2020)... , ... February 07, 2020 , ... ... consulting firm for the natural health product, nutraceutical and dietary supplement industries, announces ... been a leader in regulatory expertise and research pertaining to probiotics. We are ...
Breaking Biology News(10 mins):